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Mortality rate is high in psychiatric patients versus general population. An important cause
of this increased mortality is sudden cardiac death (SCD) as a major side-effect of psy-
chotropic drugs. These SCDs generally result from arrhythmias occurring when the posol-
ogy is high and may attain a toxic threshold but also at dosages within therapeutic range,
in the presence of risk factors.There are three kinds of risk factors: physiological (e.g., low
cardiac rate of sportsmen), physiopathological (e.g., hepatic insufﬁciency, hypothyroidism)
and “therapeutic” (due to interactions between psychotropic drugs and other medicines).
Association of pharmacological agents may increase the likelihood of SCDs either by (i) a
pharmacokinetic mechanism (e.g., increased torsadogenic potential of a psychotropic drug
when its destruction and/or elimination are compromised) or (ii) a pharmacodynamical
mechanism (e.g., mutual potentiation of proarrhythmic properties of two drugs). In addi-
tion, some psychotropic drugsmay induce sudden death in cases of pre-existing congenital
cardiopathies such as (i) congenital long QT syndrome, predisposing to torsade de pointes
that eventually cause syncope and sudden death. (ii) A Brugada syndrome, thatmay directly
cause ventricular ﬁbrillation due to reduced sodium current through Nav1.5 channels. More-
over, psychotropic drugs may be a direct cause of cardiac lesions also leading to SCD.This
is the case, for example, of phenothiazines responsible for ischemic coronaropathies and
of clozapine that is involved in the occurrence of myocarditis. The aims of this work are
to delineate: (i) the risk of SCD related to the use of psychotropic drugs; (ii) mechanisms
involved in the occurrence of such SCD; (iii) preventive actions of psychotropic drugs side
effects, on the basis of the knowledge of patient-speciﬁc risk factors, documented from
clinical history, ionic balance, and ECG investigation by the psychiatrist.
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INTRODUCTION
The overall mortality rate in psychiatric patients is two- to ﬁve-
fold higher than in the general population (Brown, 1997; Harris
and Barraclough, 1998; Ruschena et al., 1998; Raedler, 2010) and
their life expectancy is approximately 20% shorter (Newman and
Bland, 1991). Mortality is higher in male than in female patients,
especially when they are young (Hansen et al., 1997). This excess
in mortality is partly linked to the use of psychotropic drugs,
especially anti-depressants and neuroleptics (Frassati et al., 2004;
Raviña et al., 2007b; Alvarez and Pahissa, 2010), but also amphet-
amines (Yim et al., 2008) and amphetamine-like derivatives, such
as methylphenidate (Langendijk and Wilde, 2006) or lithium salts
(Yap et al., 2009).
Death occurs more frequently in patients with extra-cardiac
(hypokalemia, drug interactions) or cardiac risk factors (bradycar-
dia, ischemia, dilated or hypertrophic cardiomyopathies, arrhyth-
mogenic cardiopathies of the right ventricle, or other arrhyth-
mias). Sudden death has indeed been reported in patients whose
medical history included depolarization disorders, e.g.: reentry
arrhythmia, such as Brugada syndrome. Right branch block with
elevation of ST segment, a characteristic feature of Brugada syn-
drome, has been described during treatment with several psy-
chotropic drugs (Rouleau et al., 2001). Thus, anti-depressants that
selectively inhibit serotonin reuptake (SISR), such as ﬂuvoxamine,
or psychotropic drugs that decrease Na+ entry via Nav1.5 chan-
nels (SCN5A) should not be prescribed to patients with abnormal
Nav1.5 channels (Stirnimann et al., 2010) as this could worsen
ECGalterations.Moreover, lithium salts induce ECGchanges close
to Brugada syndrome (Darbar et al., 2005). In addition, the med-
ical history of patientswith suddendeath of cardiac origin includes
repolarization disorders (e.g. prolonged QT interval). Indeed, a
congenital or acquired long QT syndrome is an important cause
of sudden death owing to pre-existing mutations of ion channels
(in particular hERG channels), that predispose to fatal ventricular
arrhythmias including torsades de pointe (TdP) potentially result-
ing in ventricular ﬁbrillation (VF; Killeen, 2009). Voltage-clamp
electrophysiological studies have shown that SISR, such as ﬂuox-
etine and norﬂuoxetine, one of its metabolites, selectively block
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hERG channels via two different mechanisms: (i) direct channel
blockade, and (ii) disruption of channel protein trafﬁcking (Raja-
mani et al., 2006). Recently,Lee et al. (2009) reported that sulpiride,
a benzamide neuroleptic drug, can prolong the QT interval. These
authors using the patch-camp technique on Purkinje ﬁbers and
mammalian cells transfectedwith hERG,KCNQ1/KCNE1,KCNJ2,
and SCN5A cDNA, and rat myocytes overexpressing ICa showed
that sulpiride increased the duration of action potentials owing
to a signiﬁcant reduction in IKr while its effects on INa, ICa, IKs,
and IK1 currents were not signiﬁcant. The prolongation of the QT
interval by this neuroleptic drug is therefore linked to a blockade
of hERG channels.
The results mentioned above clearly suggest that anti-
depressants and neuroleptics can affect several ion channels
involved in the control of cardiac action potentials, and thus exert
a proarrhythmic activity. A better understanding of genetics in
this area can help clinicians to prevent life-threatening adverse
events.Anumberof genes including SCN5A,SCN4B,CACNL1AC,
KCNH2, KCNQ1, KCNE1, ANK2, ALG10, KCNJ2, KCNE2, RYR2,
KCND3, KCND2, ACE, NOS1AP, CASQ2 and Rad have been
associated with arrhythmias, and are good candidates to deﬁne
a proarrhythmic genetic proﬁle (Drago et al., 2008). Therefore,
before prescribing anti-depressants and neuroleptics drugs, clini-
cians should be aware of known interactions of several genes (e.g.
SCN5A, LQT1, LQT2, LQT3, LQT8) with these drugs in order to
achieve a safer therapeutic use. Navedo et al. (2010) have shown
the presence of a mutated calcium channel (Cav1.2) in Timo-
thy syndrome that may induce arrhythmia and autism in humans
(LQT8). However, to the best of our knowledge, no study showing
interferences between psychotropic drugs and Cav1.2 has yet been
published.
The objective of the present paper is to review the risk fac-
tors of sudden death of cardiac origin associated with the use of
psychotropic drugs, the underlying mechanisms, and preventive
measures.
SUDDEN DEATHS OF CARDIAC ORIGIN ASSOCIATED WITH
PSYCHOTROPIC DRUGS
Sudden death of cardiac origin associated with the use of psy-
chotropic drugs can occur in patients with pre-existing car-
diopathies including ischemic, dilated, and hypertrophic car-
diopathies. However, it is possible that psychotropic drugs can
by themselves induce such pathological conditions.
PSYCHOTROPIC DRUGS AND ISCHEMIC CARDIOPATHIES
Several psychotropic drugs can induce thrombosis or coronary
spasm, or even myocardial infarct (MI). Thorogood et al. (1992)
observed a 17-fold increase in the risk of fatal MI (relative risk:
16.9, 95% conﬁdence interval: 3.9–72.8) associated with the use of
psychotropic drugs. Moreover, several studies highlighted the high
incidence of ischemic cardiopathies correlated to the nature of the
psychiatric disease. Thus, Jin et al. (2011) compared the risk of
ischemic cardiopathy development in middle age and elderly psy-
chotic patients with the general population over a 10-year period.
After excluding patients with a history of coronary disease or cere-
bral vascular accident, 179 patients were included. Of these, 68
had schizophrenia, 42 mood disorders, 38 insanity, and 31 severe
depressions. Selected criteria for the analysis included previous
medical and pharmacological treatments, physical examination,
and the metabolic proﬁle of patients. In order to assess the risk of
developing ischemic cardiopathies according to the Framingham
Heart Study (Levy et al., 1990), the authors calculated the risk of
coronary disease in each patient, and then compared the relative
risk associated with each psychiatric diagnosis. Compared to the
general population, they found a 79% risk increase in patients with
schizophrenia, 72% with depression, 61% with mood disorders
related to psychosis, and 11% with dementia.
In addition, the analysis of the medical history and post-
mortem ﬁndings from 850 patients with schizophrenia who died
from 1952 to 2007 found a tremendous increase in the incidence
of pathological cardiac conditions, particularly chronic ischemic
cardiopathy,MI anddilated cardiomyopathies. These ﬁndingsmay
have been at least partly related to the long-term use of phenoth-
iazine neuroleptics by schizophrenic patients (Volkov, 2009). It
seems that the increased incidences of ischemic cardiopathies as
well as the highmorbidity andmortality rate in patientswith schiz-
ophrenia are linked to treatments with atypical anti-psychotics.
Indeed, such treatments are associated with metabolic disorders
including weight gain, dyslipidemia, and deregulation of glucose
metabolism, which have been suggested to increase the risk of
coronary disease and diabetes in this population (Barnett et al.,
2009).
A number of studies highlighted the existence of ischemic car-
diopathies discovered at necropsy in patients previously treated
with psychotropic drugs and who died of sudden cardiac death
(Frassati et al., 2004). Recently, Suvisaari et al. (2010) studied the
prevalence of coronary disease and MI in patients with psychotic
disorders. They searched for anomalies of the cardiac conduction
and the role of anti-psychotic drugs. The study was based on a
representative national survey of 8,028 Finnish patients aged over
30 years. The diagnosis of coronary disease and MI was obtained
from clinical and ECG ﬁndings. A number of ECG recordings
evidenced large Q waves suggestive of a former MI. They were
signiﬁcantly more frequent in patients with schizophrenia than
in patients without a medical history of psychiatric disorders.
Overall, these results support the conclusion that ischemic car-
diopathies are more frequent in patients with schizophrenia. One
explanation could be at least in part that neuroleptic drugs could
play a role by inducing metabolic disorders resulting in ischemic
cardiopathies.
PSYCHOTROPIC DRUGS AND CONGENITAL CARDIOPATHIES
The incidence of sudden death associated with psychotropic
drugs is very high in patients with various types of congenital
cardiopathies.
The causative role of the amphetamine-likedrugmethylphenidate
in sudden deaths occurring in teenagers have been highlighted by
Langendijk and Wilde (2006) who reported 25 cases of sudden
death deﬁned according to the World Health Organization crite-
ria following the use of methylphenidate and other amphetamine
derivatives. The majority of victims were less than 18 years of age
and the most fatal arrhythmias developed in teenagers with a con-
genital cardiopathy including the long QT congenital syndrome or
a hypertrophic cardiomyopathy.
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Lithium salts that are widely used in the treatment of bipo-
lar disorders are also associated with cardiac complications such
as myocarditis (Talati et al., 2009), severe bradycardia (Waring,
2007), prolongation of the QT interval (van Noord et al., 2009),
and severe ventricular arrhythmias potentially leading to VF and
sudden death (Cruchaudet et al., 2002). Recently, a case of Bru-
gada syndrome was reported in a 78-year-old patient with severe
depression treated for 25 years with imipramine, amineptine,
levomepromazine, and lorazepam. The addition of lithium salts
induced a right branch block with elevation of the ST segment,
reminiscent of a Brugada syndrome (Figure 1).
Accordingly, the use of psychotropic drugs that interfere with
the fast Na+ current and can cause reentry arrhythmias (Pacher
and Kecskeméti, 2004) is contra-indicated in patients with Bru-
gada syndrome (Antzelevitch et al., 2005; Table 1). Indeed, the
density of Na+ channels is reduced in these patients, which
results in depressed membrane depolarization of ventricular car-
diomyocytes (Brugada et al., 2005, 2009; Sicouri and Antzelevitch,
2008).
Amajority of neuroleptics can prolong theQT interval and lead
to TDP. This risk is particularly high in those patients with alter-
ations of a structure or regulatory protein. Prolongation of the
QT interval can be due to an improper inactivation of: (i) the Na
channel Nav 1.5 (persistingNa+ current throughmutated SC5NA,
responsible of LQT3) as is seen in the Romano-Ward syndrome
characterized by prolonged QT interval and anomalies of T waves
potentially leading to TDP; or (ii) the Ca channel Cav 1.2 (per-
sisting Ca channel current responsible for LQT8) as is seen in the
Timothy syndrome combining LQT8 and autism.A prolonged QT
interval can also result from the loss of activity in the IKs (LQT1,
LQT5) or IKr (LQT2, LQT6) channels, or from alterations of regu-
latory proteins, such as ankyrin B (LQT4) or caveolin 3 (LQT9) or
the KvLQT1 protein (Romano Ward and Jervell syndrome). TDP
have also been reported in patients treatedwith psychotropic drugs
that block HERG (IKr) channels (acquired long QT syndrome:
LQT1 and LQT2).
MECHANISMS INVOLVED IN SUDDEN DEATHS OF CARDIAC
ORIGIN
Three main mechanisms can be involved in sudden deaths
of cardiac origin: electrophysiological disturbances, myocardial
ischemia, and myocarditis.
SUDDEN DEATH DUE TO ELECTROPHYSIOLOGICAL DISTURBANCES
The involved disturbances include either depolarization or repo-
larization disturbances.
Depolarization in ventricular cells depends on the fast Na+
inward current (Figure 2), the inhibition of which can induce
reentry arrhythmias potentially resulting in VF. Disturbances of
ventricular depolarization, which reﬂect delayed intra-ventricular
depolarization, can be induced by many drugs that inhibit the
entry of Na+ ions in ventricular cardiomyocytes. These include
neuroleptics (LoVecchio et al., 1996) and tricyclic anti-depressants
(Leonard et al., 1995) when used alone or combined (Wilens et al.,
1990). Moreover, tricyclic anti-depressants behave as class I antiar-
rhythmics, that is to say they can inhibit the fast Na+ current
(Mladosievicova et al., 1996). They can induce reentry arrhythmias
(Figure 3) such as isolated or bursts of ventricular extra-systoles
(VES),bigeminy, ventricular tachycardia (VT), ventricular ﬂutters,
or even VF and, in this case, sudden death.
Sudden deaths of cardiac origin can also be due to distur-
bances of repolarization. Psychotropic drugs that prolong the QT
interval and can induce TDP include neuroleptics (Warner et al.,
Table 1 | Psychotropic drugs contra-indicated in patients with Brugada
syndrome (Antzelevitch et al., 2005).
Therapeutic class International denomination
Tricyclic anti-depressants Clomipramine
Tetracyclic anti-depressants Maprotiline
Inhibitors of serotonin reuptake Fluoxetine
Phenothiazine neuroleptics Cyamemazine
FIGURE 1 | Brugada syndrome. A=normal ECG; B=Brugada syndrome with right branch block and elevation of the ST segment.
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FIGURE 2 | Development of action potential in the His–Purkinje
system: passive ion movements (phase 0, 1, 2, and 3), and then active
ionic movements (ATPase-dependent during diastole). Lower trace:
correlation with ECG recording.
FIGURE 3 | Reentry arrhythmias.They affect a restricted area
(micro-reentry) or a large area (macro-reentry) of the myocardium.When
the excitation wave goes down the intra-cardiac system that is blocked by
an area in refractory period (A), it travels around and may excite it in a
retrograde direction (the abnormal zone meanwhile comes out of its
refractory period, see (B). Then, the wave having reached the initial
blockade point can, this time, travel in the normal direction (anterograde) to
neighbor non-refractory ﬁbers and cause a new premature contraction (C).
This can originate an excitation wave rotating within a closed circle and that
may propagate to adjacent myocardial tissues. NB: An identical
phenomenon may occur in cases of myocardial ischemia, with a slowing
down of intra-ventricular conduction in the ischemic area. The excitation
wave reaches tissue that is no longer in refractory period and can travel in
reverse direction, and thus, may cause reentry arrhythmias.
1996; Kitayama et al., 1999) and tricyclic anti-depressants (Raja-
mani et al., 2006). The most common causes include: (i) drugs
such as antiarrhythmics, quinine, halofanthrine, neuroleptics, and
tricyclic anti-depressants; (ii) ionic disturbances (hypokalemia);
(iii) congenital anomalies (Jervell and Lange-Nielsen syndrome,
Romano-Ward syndrome).
Among neuroleptics, old neuroleptics can be involved. Mehto-
nen et al. (1991) reported 49 cases of sudden death including 31
female and 18 male patients. Of these, 46 were treated with a
therapeutic dose of a phenothiazine including thioridazine alone
in 15 patients and combined with a tricyclic anti-depressant in
5 patients. The authors concluded that the cause of death was
TDP resulting from prolonged QT interval. Recent neurolep-
tics can also be involved. Prolongation of the QT interval has
been described with olanzapine (Olanzapine: New Preparation,
1999). Risperidone has also been incriminated in prolonged QTc
(>450ms) followed by TDP. Raviña et al. (2007a) reported the
death of an elderly woman treated with neuroleptics in which
a ECG Holter recording has evidenced TDP that degenerated to
VF. In addition, Pacher and Kecskemeti (2004) published pro-
longation of the QT interval in patients treated with atypical
neuroleptics such as olanzapine, risperidone, sertindole, ziprasi-
done, quetiapine, and aripiprazole. The magnitude prolonged QT
interval by aripiprazole has been highlighted by the US FDA in
2002 with 30-ms prolongation in 3.7% of patients treated with
30mg/day versus 6ms in patients under placebo. The magnitude
of QTc prolongation is dose- and drug-dependent, which reﬂects
the variable propensity of psychotropic drugs to interact with ion
channels in the heart. Thoridazine and ziprasidone have been
more often incriminated in QT prolongation and TDP, and this
is due to the blockade of hERG channels, which facilitates early
depolarizing post-potentials that may result in TDP (Figure 4)
that can degenerate to VF in some instances. TDP can also be
linked to the persistence of the Na+ channel (LQT 3) or calcium
channel (LQT8).
NB: The early after-depolarizations (EADs) are related to the
activation of L-type calcium channels. These EADs are capa-
ble of inducing re-excitation and ventricular arrhythmias. The
prolongation of this phase may, especially when it is heteroge-
neous, lead to torsades de pointes. This prolongation is either
congenital (congenital long QT syndrome) or due to various drug
intakes (acquired longQT syndrome, i.e., iatrogenic). Their occur-
rence ismainly favored by bradycardia and/or hypokalemia. Drugs
potentially torsadogenic belong to many classes of drugs (see
below).
Tricyclic anti-depressants
Curtis et al. (2003) retrospectively studied 4,825,345 patients aged
over 18 years and identiﬁed 50 drugs with a high potential for
inducing prolonged QT interval and 26 drugs that decrease the
metabolic clearance of other drugs that prolong the QT interval.
Among 1.1 million patients (22.8%) treated with a drug prolong-
ing the QT interval, 103,119 (9.4%) were treated with 2 or more
TDP-inducing drugs, or with a drug prolonging the QT interval
combined with another drug inhibiting its hepatic metabolism. In
addition, 7,249 (0.7%) were treated with 3 or more drugs prolong-
ing the QT interval. Overall, 22% of patients were over 65 years
of age and 74% were women. Anti-depressants were involved in
nearly 50% of patients with prolonged QT interval. One recent
ﬁnding is that anti-depressants, which speciﬁcally inhibit sero-
tonin reuptake (ISRS), can prolong the QT interval (Rajamani
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FIGURE 4 |Torsades de pointes.
Table 2 | Psychotropic drugs recognized by the Advisory Council of
Arizona to have a real risk of torsades de pointes.
International
denomination
Commercial
denomination
Therapeutic class
Haloperidol Haldol® Anti-psychotic/schizophrenia,
agitation
Thioridazine Mellaril® Anti-psychotic/schizophrenia
Mesoridazine Serentil® Anti-psychotic/schizophrenia
Chlorpromazine Thorazine® Anti-psychotic/anti-emetic/
schizophrenia/nausea
Table 3 | Psychotropic drugs implicated in the prolongation of the QT
interval and in the genesis of torsades de pointes, but with a lack of
sufficient evidence.
International
denomination
Commercial
denomination
Therapeutic class
Clozapine Clozaril® Anti-psychotic/schizophrenia
Escitalopram Lexapro® Anti-depressant/major
depression/anxiety disorders
Escitalopram Cipralex® Anti-depressant/major
depression/anxiety disorders
Paliperidone Invega® Anti-psychotic, atypical/schizophrenia
Quetiapine Seroquel® Anti-psychotic/schizophrenia
Risperidone Risperdal® Anti-psychotic/schizophrenia
Sertindole Serdolect® Anti-psychotic, atypical/anxiety,
schizophrenia
Sertindole Serlect® Anti-psychotic, atypical/anxiety,
schizophrenia
Venlafaxine Effexor® Anti-depressant/depression
Ziprasidone Geodon® Anti-psychotic/schizophrenia
et al., 2006). The role of ISRS is highlighted by prolongation of the
QT interval in neonates whose mother has been treated with ISRS
during pregnancy (Dubnov et al., 2005).
The Arizona Center for Education and Research on Therapeu-
tics (The Critical Path Institute, Tucson, Arizona, and Rockville,
MD, USA) proposed a classiﬁcation based on the potential for
psychotropic drugs to prolong the QT interval and induce TDP
(Tables 2–4).
Table 4 | Psychotropic drugs, which in some studies, were weakly
associated with QT interval prolongation and/or torsades de pointes.
International
denomination
Commercial
denomination
Therapeutic class
Amitriptyline Elavil® Tricyclic anti-depressant/depression
Citalopram Celexa® Anti-depressant/depression
Clomipramine Anafranil® Tricyclic anti-depressant/depression
Desipramine Pertofrane® Tricyclic anti-depressant
Doxepin Sinequan® Tricyclic anti-depressant/depression
Fluoxetine Sarafem® Anti-depressant/depression
Fluoxetine Prozac® Anti-depressant/depression
Imipramine Norfranil® Tricyclic anti-depressant/depression
Nortriptyline Pamelor® Tricyclic anti-depressant/depression
Paroxetine Paxil® Anti-depressant/depression
Protriptyline Vivactil® Tricyclic anti-depressant/depression
Sertraline Zoloft® Anti-depressant/depression
Trazodone Desyrel® Anti-depressant/depression, insomnia
Trimipramine Surmontil® Tricyclic anti-depressant/depression
However, the risk of torsades de pointes is low when used at recommended
doses and/or in patients without risk factors (e.g., bradycardia, electrolyte distur-
bances and congenital long QT syndrome, in association with inhibitors of CYP
450 responsible for the metabolism of psychotropic drugs concerned).
NB. Classiﬁcation of Arizona does not include all psychotropic drugs that may pro-
long the QT interval and cause torsades de pointes.This is the case, for example,
of pimozide. It is necessary therefore to be especially careful and evaluate the
risk for non-listed drugs. NB. Actions to be taken when prescribing neuroleptics
and anti-depressants to patients with disorders of repolarization and/or treated by
antiarrhythmic drugs or other potentially torsadogenic drugs: Use a neuroleptic
or an anti-depressant at low torsadogenic potential. Make sure the ion balance,
particularly in serum potassium. Discard, if possible, the use of drugs that induce
bradycardia. Perform an ECG and an ionic balance before the introduction of
torsadogenic psychotropics (Lin et al., 2004; Narang et al., 2010). A cardiology
consultation may sometimes be necessary.
SUDDEN DEATHS DUE TO MYOCARDITIS AND MYOCARDIOPATHIES
Another mechanism of sudden death associated with the use of
neuroleptics is the development of myocarditis. One of the ﬁrst
studies to report on the responsibility of neuroleptics in the gen-
eration of myocarditis andmyocardiopathywas that of Kilian et al.
(1999) on clozapine. This Australian study included 8,000 patients
from 1993 to 1999 and described structural lesions in 23 patients
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(20 men and 3 women, mean age: 36± 9 years). Among these 23
patients, 5 had cardiomyopathy of which one died after 36 months
of treatment. The 18 remaining patients had myocarditis and 5
died (3 of sudden death and 2 of cardiac insufﬁciency) within
the 3 ﬁrst weeks of treatment. In addition, the risk of myocarditis
associated with clozapine has recently been said to be underesti-
mated (Schulte, 2011). Other reports of neuroleptics-associated
myocarditis included ﬂuphenazine, haloperidol, and risperidone
(Coulter et al., 2001).
We observed experimentally the development of myocarditis
with a number of neuroleptics including amisulpride, haloperi-
dol, levomepromazine, olanzapine, risperidone as well as com-
binations of levomepromazine and haloperidol or risperidone
(Belhani et al., 2006). Indeed, global ventricular hypertrophy was
found in rabbits treated with olanzapine and chieﬂy the com-
binations levomepromazine-haloperidol and levomepromazine–
risperidone; necrosis with amisulpride and haloperidol; endo-
cardial ﬁbrosis with levomepromazine; but no marked lesions
with risperidone. Overall, these abnormal ﬁndings are similar
to those seen in toxic myocarditis induced in previously healthy
hearts.
PREVENTION OF QTc PROLONGATION IN PATIENTS TREATED
WITH PSYCHOTROPIC DRUGS
NB: The evaluation of the risk/beneﬁt ratio for drugs that prolong
theQT/QTc interval should take into accountmorbidity/mortality
associated with the disease as well as the lack of treatment of the
disease.
The prevention of QT interval prolongation is based on a
number of parameters, which should be known to reduce the
generation of TDPs and sudden death. It is primarily based on
ECG recording and the interpretation of results, on blood ion lev-
els, on the torsadogenic potential of the (psychotropic) drug(s) of
concern, and on the existence of risk factors.
Risk factors for the prolongation of the QT interval and the
generation of TDPs are of extra-cardiac, cardiac, and drug ori-
gin. Drug-induced TDPs mainly develop when two or more drugs
are combined, which highlights the role of drug interactions. The
existence of one or several risk factors requires ECG recording
prior to treatment with psychotropic drugs, especially when the
intravenous route is to be used (Meyer-Massetti et al., 2010).
RISK FACTORS OF TDP
Many risk factors have been shown to be involved in the develop-
ment of TDP, including gender (women), pre-existing cardiovas-
cular diseases (especially bradycardia), electrolytic disturbances,
and congenital long QT syndrome (Letsas et al., 2009; Alvarez
and Pahissa, 2010). They must be searched for prior to start-
ing treatment with neuroleptics or anti-depressants, and include
extra-cardiac and cardiac risk factors.
Age, and hepatic and renal function of patients
Cardiac accidents tend to be more frequent in elderly patients
because of their “physiological” decrease in hepatic and/or renal
function due to senescence (Vieweg et al., 2009). Overt hepatic
and/or renal failure can also be involved as they reduce the bio-
transformation and/or elimination of drugs. Adaptation of drug
dosage may be needed (Haddad and Anderson, 2002).
Gender
Testosterone provides some protection to men (Stöllberger et al.,
2005; Vieweg et al., 2009). The difference in the susceptibility to
TDP across gender appears after puberty only, which suggests that
sex hormones may contribute. In male humans, testosterone has
been shown to reduce the duration of the action potential and
hence of the QTc interval. In contrast, estradiol can potentiate the
effects of drugs that prolong the QT interval. Sex hormones have
been suggested to alter Ca2+ and/or K+ currents, which could
also account for differences observed in the action of drugs on the
repolarization of cardiac cells (Coker, 2008).
Genetic polymorphism
Cytochromes P450 (CYP450) are a group of enzymes specialized
in the metabolism of drugs that play a pivotal role in biotrans-
formation processes involving xenobiotics (Hasler, 1999; Nelson,
1999). CYP450 isoenzymes are involved in the metabolism of
most neuroleptics including clozapine, haloperidol, perphenazine,
risperidone, thioridazine, aripiprazole, as well as tricyclic anti-
depressants and ISRS (Wilkinson, 2005). For instance, more than
25% of drugs including anti-depressants and neuroleptics are
metabolized by CYP2D6. CYP2D6 is characterized by a wide
genetic polymorphism (approx. 80 identiﬁed alleles) and intereth-
nic variability. Slowmetabolizerswith a very lowmetabolic activity
account for 5–10% of the Caucasian population, and ultra-rapid
metabolizers from1 to 10%of theCaucasian population. They can
be affected either bymore severe adverse effects or therapeutic inef-
ﬁcacy, depending on whether or not the drug of interest should be
metabolized to become active. Intermediate (10–15%) and good
metabolizers (65–80%) have a fairly similar metabolic activity.
Phenotyping and genotyping can be useful tools to identify at-
risk patients and lead to a more effective and safer individualized
therapy. This is a very important point. Indeed, the activity of
clozapine, which is metabolized by CYP2D6, is increased in case
of deﬁciency and in turn the risk of adverse effects induced by
clozapine is increased (Jerling et al., 1994; Kang et al., 2000).
CARDIAC RISK FACTORS
Bradycardia
Whatever its origin (physiological or pathological), bradycardia
can prolong the QT interval by delaying cellular repolarization in
patients treatedwith neuroleptics (Dhein et al., 2008). There is also
a higher risk in patients treated with bradycardia-inducing drugs
such as digitalis and in patients with bradycardia of pathological
origin, such as hypothyroidism (Micallef et al., 2011).Among ECG
recorded in 688 psychiatric patients treated with psychotropic
drugs, QTc> 460ms was observed in 96 patients (14%; Sadanaga
et al., 2004). To elucidate the relationship between heart rate and
duration of the QT interval, these authors measured QT and RR
intervals by ECG Holter during 24 h in 97 patients. They showed
that for a heart rate of 80/min, the duration of the QT interval was
in the range of 400ms, and for a heart rate of 50/min, the duration
exceeded 480ms. This study stresses the heart rate-dependency of
the QT interval duration.
Slowing of supraventricular conduction
Any slowing and obviously the presence of an auriculoventricular
block (AVB) is an important risk factor of TDP (Yiginer et al.,
2010).
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Table 5 | Different types of CYP 450, their substrates, and inhibitors (Prior and Baker, 2003).
Types of CYP 450 Neuroleptic drugs
substrates of CYP450
Drugs inhibiting CYP 450
CYP 450- 1A2 Clozapine, haloperidol, olanzapine Ciproﬂoxacin, enoxacin, ﬂuvoxamine, cimetidine
CYP 450- 3A4 Clozapine, haloperidol, pimozide, ziprasidone,
aripiprazole
Fluvoxamine, ﬂuoxetine, ciproﬂoxacin, itraconazole, ketoconazole,
erythromycin, clarithromycin, indinavir, ritonavir, delavirdine, efavirenz,
methadone, amiodarone, cimetidine, nefazodone, grapefruit juice
CYP 450- 2D6 Clozapine, haloperidol, perphenazine, risperidone,
thioridazine, aripiprazole
Fluoxetine, paroxetine, cimetidine, quinidine, ritonavir, amiodarone,
clomipramine, chlorpheniramine, methadone
NB: It is noteworthy that some anti-psychotics are metabolized by several CYP 450. If one of these CYP 450 is inhibited by a drug, the metabolism of the neuroleptic
will be provided by another CYP 450 whose activity is not necessarily inhibited by the same drug. This is the case, for example, of clozapine that is metabolized by
the CYP 450 1A2, 3A4, and 2D6. If the activity of CYP 450 1A2 is inhibited by ciproﬂoxacin, enoxacin, ﬂuvoxamine, and cimetidine, the CYP 450 3A4 and 2D6 ensure,
at least in part, the metabolism of clozapine.
Table 6 | Drugs that may prolong the QT interval.
Therapeutic class Drugs involved
Class Ia antiarrhythmics Hydroquinidine, disopyramide
Class III antiarrhythmics Amiodarone, sotalol, ibutilide
Class IV antiarrhythmics Bepridil
Antibiotics (macrolis) Erythromycin
Synthetic antimalarial agents Halofantrine
Anti leishmania agents and
trypanocides
Pentamidine diisethionate
H1 antihistaminics Mizolastine: this drug slightly lengthens
the QT interval
Channelopathies
The presence of Romano Ward or Timothy syndrome consider-
ably increases the generation of TdP associated with psychotropic
drugs that can prolong the QT interval. It is absolutely required to
evaluate this risk and adapt treatment.
DRUG-RELATED RISK FACTORS: DRUG INTERACTIONS
Pharmacokinetic interactions: enzyme inhibitors
Such interactions develop in particular when psychotropic drugs
are associated with drugs that interact with various CYP450 (Prior
and Baker, 2003). Indeed, the combination of a psychotropic drug
with another drug that inhibits the enzyme involved inmetabolism
can induce an increase in plasma levels, and potentially tissue levels
with resulting toxicity. The main psychotropic drugs and CYP450
involved in their metabolism and speciﬁc enzyme inhibitors are
summarized in Table 5.
Pharmacodynamic interactions
The use of potentially torsadogenic neuroleptics increases the risk
of TDP when associated with another drug that can prolong the
QT interval (Cubeddu, 2003; Table 6). Such an association should
therefore be avoided or considered only very carefully.
Hypokalemia (Frimas et al., 2008)
Hypokalemiaof pathological or drug-inducedorigin can shift rest-
ing potential toward less negative values and thus considerably
Table 7 | Drugs responsible for hypokalemia.
Hypokalemia and
mechanisms for its
occurrence
Drugs involved
Prokinetic effect Cisapride (Prepulsid®)
Digestive loss Laxatives, Kayexalate
Urinary loss Glucocorticoids
Mineralocorticoids
High ceiling diuretics and thiazides
Glycyrrhizinic acid
β-Lactamines at high doses
Aminosides
Amphotericin B (by acute tubular necrosis)
Transfer of intracellular K+ β2 Mimetics (IV): salbutamol, adrenalin
Insulin at high doses (IV)
Blood alkalinizing drugs
FIGURE 5 | How to handle prescription of a potentially torsadogenic
psychotropic in patients at-risk.
increase the risk of TDP. It is therefore recommended to avoid
the combination of neuroleptics with hypokalemiant drugs or
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attempts to correct hypokalemia. Hypokalemia can have various
origins (Table 7):
CONCLUSION
The cardiovascular toxicity of psychotropic drugs can display var-
ious clinical manifestations including orthostatic hypotension,
syncope, myocardial ischemia, myocarditis, cardiac arrhythmias
(reentry arrhythmias, torsade de pointes. . .) among which some
may lead to sudden death. These manifestations, in particular
sudden death, are more common in patients with congenital
or acquired cardiac risk factors, including hypertrophic and/or
dilated cardiopathies, ischemic cardiopathies, combination of pre-
scribed drugs that prolong QRS complexes or QT intervals, or
drugs that can induce hypokalemia or bradycardia.
Particular precautionary measures should be taken including
blood ionic balance, ECG recording, and even cardiac echogra-
phy, to reduce the risk of cardiac adverse events that may be
life-threatening (Figure 5).
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